US FDA poised to upend best laid plans of vaccine makers

29 June 2022

Coronavirus vaccine developers have been busy updating their jabs in time for cold weather booster campaigns, but a panel of US Food and Drug Administration scientists has just thrown a wrench into the works.

Both Moderna (Nasdaq: MRNA) and Pfizer (NYSE: PFE) are engaged with the FDA to try to secure approval for new versions of their vaccines, which target both the original strain and the Omicron variant.

But the virus has already evolved, with sub-variants, specifically BA.4 and BA.5, now making up a majority of new cases in the country, according to Centers for Disease Control and Prevention (CDC) estimates.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK